The detectability of the pretreatment EGFR T790M mutations in lung adenocarcinoma using CAST-PCR and digital PCR
- PMID: 28932544
- PMCID: PMC5594155
- DOI: 10.21037/jtd.2017.07.02
The detectability of the pretreatment EGFR T790M mutations in lung adenocarcinoma using CAST-PCR and digital PCR
Abstract
Background: A gatekeeper T790M mutation is thought to cause resistance to epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) treatment. The detection of a 2nd mutation is important for planning the next therapy when patients acquire resistance to the first line EGFR-TKI.
Methods: We used a competitive allele-specific polymerase chain reaction (CAST-PCR) to analyze the incidence and clinical significance of T790M mutations in 153 lung adenocarcinomas with EGFR-activating mutations. To increase the sensitivity and specificity of the detection of T790M mutations, we subjected 20 of the 153 cases to a digital PCR. The genomic DNAs were extracted from frozen, surgically resected tumor tissue specimens.
Results: The CAST-PCR detected T790M mutations in 45 (29.4%) of the 153 cases. The analytical sensitivity in the detection T790M mutations was 0.13-2.65% (average 0.27%, median 0.20%). In contrast, the digital PCR, detected T790M mutations in 8 (40%) out of 20 cases.
Conclusions: Our study shows that the pretreatment incidence of T790M mutation was less than that reported in previous studies. In order to clinically use pretreatment EGFR T790M mutation identification method, we should clarify the adequate methods and tissue preserved status.
Keywords: CAST-PCR; EGFR mutation; Non-small cell lung cancer (NSCLC); T790M mutation; digital PCR.
Conflict of interest statement
Conflicts of Interest: The authors have no conflicts of interest to declare.
Figures



Similar articles
-
Picoliter-Droplet Digital Polymerase Chain Reaction-Based Analysis of Cell-Free Plasma DNA to Assess EGFR Mutations in Lung Adenocarcinoma That Confer Resistance to Tyrosine-Kinase Inhibitors.Oncologist. 2016 Feb;21(2):156-64. doi: 10.1634/theoncologist.2015-0288. Epub 2016 Jan 14. Oncologist. 2016. PMID: 26768482 Free PMC article.
-
Ultra-Sensitive Detection of the Pretreatment EGFR T790M Mutation in Non-Small Cell Lung Cancer Patients with an EGFR-Activating Mutation Using Droplet Digital PCR.Clin Cancer Res. 2015 Aug 1;21(15):3552-60. doi: 10.1158/1078-0432.CCR-14-2151. Epub 2015 Apr 16. Clin Cancer Res. 2015. PMID: 25882755
-
Most T790M mutations are present on the same EGFR allele as activating mutations in patients with non-small cell lung cancer.Lung Cancer. 2017 Jun;108:75-82. doi: 10.1016/j.lungcan.2017.02.019. Epub 2017 Mar 1. Lung Cancer. 2017. PMID: 28625653
-
Highly sensitive detection of EGFR T790M mutation using colony hybridization predicts favorable prognosis of patients with lung cancer harboring activating EGFR mutation.J Thorac Oncol. 2012 Nov;7(11):1640-4. doi: 10.1097/JTO.0b013e3182653d7f. J Thorac Oncol. 2012. PMID: 22899358
-
Germline EGFR mutations in lung cancer (Review).Oncol Lett. 2023 May 16;26(1):282. doi: 10.3892/ol.2023.13868. eCollection 2023 Jul. Oncol Lett. 2023. PMID: 37274482 Free PMC article. Review.
Cited by
-
Prognostic impact of pretreatment T790M mutation on outcomes for patients with resected, EGFR-mutated, non-small cell lung cancer.BMC Cancer. 2022 Jul 15;22(1):775. doi: 10.1186/s12885-022-09869-7. BMC Cancer. 2022. PMID: 35840951 Free PMC article.
-
[Advanced Research on Non-small Cell Lung Cancer with De Novo T790M Mutation].Zhongguo Fei Ai Za Zhi. 2019 May 20;22(5):324-328. doi: 10.3779/j.issn.1009-3419.2019.05.10. Zhongguo Fei Ai Za Zhi. 2019. PMID: 31109443 Free PMC article. Review. Chinese.
-
Highly Sensitive 3D-Nanoplasmonic-Based Epidermal Growth Factor Receptor Mutation Multiplex Assay Chip for Liquid Biopsy.Small Sci. 2024 Jun 26;4(8):2400101. doi: 10.1002/smsc.202400101. eCollection 2024 Aug. Small Sci. 2024. PMID: 40212553 Free PMC article.
-
Significance of micro-EGFR T790M mutations on EGFR-tyrosine kinase inhibitor efficacy in non-small cell lung cancer.Sci Rep. 2023 Nov 13;13(1):19729. doi: 10.1038/s41598-023-45337-3. Sci Rep. 2023. PMID: 37957228 Free PMC article.
-
Technical Validation and Clinical Implications of Ultrasensitive PCR Approaches for EGFR-Thr790Met Mutation Detection in Pretreatment FFPE Samples and in Liquid Biopsies from Non-Small Cell Lung Cancer Patients.Int J Mol Sci. 2022 Jul 31;23(15):8526. doi: 10.3390/ijms23158526. Int J Mol Sci. 2022. PMID: 35955661 Free PMC article.
References
-
- Fukuoka M, Wu YL, Thongprasert S, et al. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol 2011;29:2866-74. 10.1200/JCO.2010.33.4235 - DOI - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous